Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of$ 0.86. This compares to loss of $0.94 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -9.30%. A quarter ago, it was expected that this company would post a loss of$ 0.84 per share when it actually produced a loss of $0.93, delivering a surprise of -10.71%. Over the last four quarters, the c ...